Literature DB >> 24495859

Influence of proteolytic-antiproteolytic enzymes and prooxidative-antioxidative factors on proteoglycan alterations in children with juvenile idiopathic arthritis.

Katarzyna Winsz-Szczotka1, Katarzyna Komosińska-Vassev2, Kornelia Kuźnik-Trocha2, Anna Gruenpeter3, Iwona Lachór-Motyka3, Krystyna Olczyk4.   

Abstract

OBJECTIVES: The influence of proteolytic-antiproteolytic enzymes and prooxidative-anti-oxidative factors on proteoglycan alterations in children with juvenile idiopathic arthritis (JIA) was evaluated in this study. DESIGN, METHODS,
RESULTS: Plasma and urinary glycosaminoglycans (GAGs), as well as plasma levels of matrix metalloproteinases (MMPs) (MMP-3, MMP-10), tissue inhibitors of metalloproteinases (TIMPs) (TIMP-1, TIMP-2), total oxidative status (TOS) and total antioxidative status (TAS), were quantified in samples obtained from 30 healthy subjects and 30 JIA patients before and after treatment. Significantly decreased plasma and urinary concentration of GAGs in JIA patients before treatment was observed. Therapy resulted in an increase in the concentration of the above listed parameters. However, the plasma GAG level still remained significantly lower compared to that in controls. Increased levels of MMP-3 and TIMP-1 in both JIA patient groups were recorded. The plasma MMP-10 and TIMP-2 concentrations in untreated patients were significantly decreased. Anti-inflammatory treatment led to normalization of these parameter concentrations. Significant increase of TOS but decrease of TAS was found in the blood of untreated patients. The treatment resulted only in the normalization of TOS concentration. We have revealed a significant correlation between plasma GAGs and: MMP-3 (r=0.54), TOS (r=0.64) and urinary GAGs (r=0.55), respectively.
CONCLUSIONS: Proteoglycan/glycosaminoglycan alterations in JIA patients, which are stimulated by MMP-3 and reactive oxygen species (ROS), indicate rather systemic disturbance of extracellular matrix metabolism, and not merely local changes which occur in articular structures. Given the destructive potential of ROS and MMPs and their hyperexpression in JIA, inhibition of these compounds should bring a substantial clinical benefit.
Copyright © 2014 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Extracellular matrix remodeling; Juvenile idiopathic arthritis; Matrix metalloproteinases; Oxidative stress; Tissue inhibitors of metalloproteinases

Mesh:

Substances:

Year:  2014        PMID: 24495859     DOI: 10.1016/j.clinbiochem.2014.01.027

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  10 in total

1.  Hyaluronic Acid Therapy in Hip OA Does Not Perform Equally in Osteoarthritis Secondary to Juvenile Idiopathic Arthritis When Compared to Primary Osteoarthritis: A 2-Year Preliminary Evaluation.

Authors:  Rolando Cimaz; Roberto Caporali; Orazio De Lucia; Angela Flavia Luppino; Francesca Pregnolato; Antonella Murgo; Irene Pontikaki; Maurizio Gattinara; Tania Ubiali
Journal:  Adv Ther       Date:  2022-01-16       Impact factor: 3.845

2.  The association of CAT-262C/T polymorphism with catalase activity and treatment response in juvenile idiopathic arthritis.

Authors:  Jelena Bašić; Jelena Vojinović; Tatjana Jevtović-Stoimenov; Milena Despotović; Tatjana Cvetković; Dragana Lazarević; Gordana Sušić; Vuk Milošević; Mina Cvetković; Dušica Pavlović
Journal:  Rheumatol Int       Date:  2019-01-24       Impact factor: 2.631

3.  Concerted Actions by PIICP, CTXII, and TNF-α in Patients with Juvenile Idiopathic Arthritis.

Authors:  Katarzyna Winsz-Szczotka; Kornelia Kuźnik-Trocha; Iwona Lachór-Motyka; Wojciech Lemski; Krystyna Olczyk
Journal:  Biomolecules       Date:  2021-04-28

4.  Laboratory Indicators of Aggrecan Turnover in Juvenile Idiopathic Arthritis.

Authors:  Katarzyna Winsz-Szczotka; Kornelia Kuźnik-Trocha; Katarzyna Komosińska-Vassev; Agnieszka Jura-Półtorak; Krystyna Olczyk
Journal:  Dis Markers       Date:  2016-01-27       Impact factor: 3.434

5.  Discovery of tear biomarkers in children with chronic non-infectious anterior uveitis: a pilot study.

Authors:  Sheila T Angeles-Han; Steven Yeh; Purnima Patel; Duc Duong; Kirsten Jenkins; Kelly A Rouster-Stevens; Mekibib Altaye; Ndate Fall; Sherry Thornton; Sampath Prahalad; Gary N Holland
Journal:  J Ophthalmic Inflamm Infect       Date:  2018-10-16

6.  Association of Circulating COMP and YKL-40 as Markers of Metabolic Changes of Cartilage with Adipocytokines in Juvenile Idiopathic Arthritis.

Authors:  Katarzyna Winsz-Szczotka; Kornelia Kuźnik-Trocha; Anna Gruenpeter; Magdalena Wojdas; Klaudia Dąbkowska; Krystyna Olczyk
Journal:  Metabolites       Date:  2020-02-10

Review 7.  Alterations of Extracellular Matrix Components in the Course of Juvenile Idiopathic Arthritis.

Authors:  Magdalena Wojdas; Klaudia Dąbkowska; Katarzyna Winsz-Szczotka
Journal:  Metabolites       Date:  2021-02-25

8.  The Effects of TNF-α Inhibition on the Metabolism of Cartilage: Relationship between KS, HA, HAPLN1 and ADAMTS4, ADAMTS5, TOS and TGF-β1 Plasma Concentrations in Patients with Juvenile Idiopathic Arthritis.

Authors:  Kornelia Kuźnik-Trocha; Katarzyna Winsz-Szczotka; Iwona Lachór-Motyka; Klaudia Dąbkowska; Magdalena Wojdas; Krystyna Olczyk; Katarzyna Komosińska-Vassev
Journal:  J Clin Med       Date:  2022-04-04       Impact factor: 4.241

9.  Plasma Glycosaminoglycans in Children with Juvenile Idiopathic Arthritis Being Treated with Etanercept as Potential Biomarkers of Joint Dysfunction.

Authors:  Magdalena Wojdas; Klaudia Dąbkowska; Kornelia Kuźnik-Trocha; Grzegorz Wisowski; Iwona Lachór-Motyka; Katarzyna Komosińska-Vassev; Krystyna Olczyk; Katarzyna Winsz-Szczotka
Journal:  Biomedicines       Date:  2022-07-31

10.  GAAGs, COMP, and YKL-40 as Potential Markers of Cartilage Turnover in Blood of Children with Juvenile Idiopathic Arthritis Treated with Etanercept-Relationship with ADAMTS4, ADAMTS5, and PDGF-BB.

Authors:  Klaudia Dąbkowska; Magdalena Wojdas; Kornelia Kuźnik-Trocha; Grzegorz Wisowski; Anna Gruenpeter; Katarzyna Komosińska-Vassev; Krystyna Olczyk; Katarzyna Winsz-Szczotka
Journal:  J Clin Med       Date:  2022-08-29       Impact factor: 4.964

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.